Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-5: loncastuximab tesirine + rituximab vs immunochemotherapy in relapsed/refractory DLBCL
2020-000241-14Phase 3Active
- Sponsor
- ADC Therapeutics
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by ADC Therapeutics. Primary endpoint: Progression-free survival. Started Oct 2020; status: active.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-000241-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000241-14.